Tideglusib

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameTideglusib
Drug Alias Name替德谷司TideglusibumNyptaZentylorAMO-02 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsAutism Spectrum DisorderCardiomyopathiesAmyotrophic Lateral Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNoscira Sa
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of ZurichAmo Pharma LtdBrock University
Inactive CompaniesUniversity of TorontoNoscira SaMcmaster University +[4] 
Active IndicationsCardiomyopathiesAmyotrophic Lateral SclerosisMyotonic Dystrophy
Inactive IndicationsAutism Spectrum DisorderAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksWikipedia